These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 10351162)

  • 41. Quality assurance and standards for red cells and platelets.
    Sweeney J
    Vox Sang; 1998; 74 Suppl 2():201-5. PubMed ID: 9704446
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of sampling procedures for quality monitoring of red cell concentrates: the need for improving sampling and sample handling techniques of red cell concentrate.
    Seghatchian MJ; Krailadsiri P; Sutherland J; Vasconcelos E; de Sousa G
    Transfus Sci; 1998 Dec; 19(4):393-8. PubMed ID: 10351166
    [No Abstract]   [Full Text] [Related]  

  • 43. [Labile blood products and their preparation].
    Chabanel A; Folléa G
    Rev Prat; 2001 Jun; 51(12):1306-10. PubMed ID: 11503503
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Blood collection and the labile blood components: what should the regulators ask for?
    Maniatis A; Adamides E
    Vox Sang; 1998; 74 Suppl 2():523-5. PubMed ID: 9704493
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Universal leukoreduction of cellular and plasma components: process control and performance of the leukoreduction process.
    Masse M
    Transfus Clin Biol; 2001 Jun; 8(3):297-302. PubMed ID: 11499981
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A platelet quality assessment scheme for comparing the performance of quality monitoring laboratories in the UK National Blood Service.
    Seghatchian J; Krailadsiri P; Rigsby P; Bukasa A; Bashir S
    Transfus Apher Sci; 2002 Feb; 26(1):83-90. PubMed ID: 11931381
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Guidelines on the clinical use of leucocyte-depleted blood components. British Committee for Standards in Haematology, Blood Transfusion Task Force.
    Transfus Med; 1998 Mar; 8(1):59-71. PubMed ID: 9569462
    [No Abstract]   [Full Text] [Related]  

  • 48. Leucodepletion process performance variation: is it dependent on the batch of filters, the processing centre or the counting technology?
    Beckman N; Seghatchian J
    Transfus Sci; 2000 Oct; 23(2):113-8. PubMed ID: 11035272
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Quality assurance in blood transfusion: the advantages and limitations].
    Hergon E
    Transfus Clin Biol; 1998 Apr; 5 Suppl 1():36S-41S. PubMed ID: 9622844
    [No Abstract]   [Full Text] [Related]  

  • 50. [Scandinavian recommendations for transfusion medicine].
    Eklund J; Jørgensen J; Högman C; Jensson O; Kornstad L
    Nord Med; 1991; 106(11):299-300. PubMed ID: 1945807
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The quality of blood starts with its collection.
    Loos JA
    Vox Sang; 1994; 67 Suppl 3():77-9. PubMed ID: 7975516
    [No Abstract]   [Full Text] [Related]  

  • 52. Haemovigilance: concept, Europe and UK initiatives.
    McClelland B; Love E; Scott S; Williamson LM
    Vox Sang; 1998; 74 Suppl 2():431-9. PubMed ID: 9704478
    [No Abstract]   [Full Text] [Related]  

  • 53. Quality assurance and quality control in component preparation.
    Pietersz RN
    Vox Sang; 1994; 67 Suppl 3():197-9. PubMed ID: 7975492
    [No Abstract]   [Full Text] [Related]  

  • 54. British Blood Transfusion Society. Blood Component Special Interest Group Symposium. Towards 'purer and safer' blood components and blood products. London, United Kingdom, 5 May 1994. Abstracts.
    Clin Lab Haematol; 1994 Dec; 16(4):379-406. PubMed ID: 7736717
    [No Abstract]   [Full Text] [Related]  

  • 55. Quality assurance, quality control and accreditation.
    Engelfriet CP; Reesink HW; de Lange GG; Flanagan P; Solheim BG; Akerblom O; Messeter L; James V; Bruce M; O'Riordan J; Murphy W; Schönitzer D; Mayr WR; Henn G; L'Herminez PC; Kühnl P; Kluge A; Mozzi F; Rebulla F; Sirchia P; Carbonell-Uberos F; Medgyesi G; Pisacka M; Letowska M; Gustafson M; Ganz P; Rees JW; Décary F; Wendel S; Rodrigues Almeida PT; Lin CK; Tadokoro K
    Vox Sang; 2000; 79(4):253-64. PubMed ID: 11206090
    [No Abstract]   [Full Text] [Related]  

  • 56. Prestorage leukocyte reduction of cellular blood components.
    Dzik S
    Transfus Sci; 1994 Jun; 15(2):131-9. PubMed ID: 10147358
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Achieving better blood bank QA with a transfusion form.
    Scholten R
    MLO Med Lab Obs; 1989 Oct; 21(10):41-3, 46. PubMed ID: 10295651
    [No Abstract]   [Full Text] [Related]  

  • 58. [Therapy with cellular blood components].
    Eichler H; Klüter H
    Internist (Berl); 2001 May; 42(5):760-8. PubMed ID: 11400584
    [No Abstract]   [Full Text] [Related]  

  • 59. Blood components. Collection, processing, and storage.
    Schneider A
    Vet Clin North Am Small Anim Pract; 1995 Nov; 25(6):1245-61. PubMed ID: 8619264
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dual reduction in the immunologic and infectious complications of transfusion by filtration/removal of leukocytes from donor blood soon after collection.
    Rawal BD; Davis RE; Busch MP; Vyas GN
    Transfus Med Rev; 1990 Oct; 4(4 Suppl 1):36-41. PubMed ID: 2134639
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.